Kiniksa Pharmaceuticals Ltd expected to post a loss of 44  cents a share - Earnings Preview

Kiniksa Pharmaceuticals International

29/07/2022 19:33

* Kiniksa Pharmaceuticals Ltd  KNSA.OQ   KNSA.O  is expected
to show a rise in quarterly revenue when it reports  results on
August 1 (estimated). 
    * The Hamilton Bermuda-based   company is expected to report
 a
270.6% increase in revenue to $28.553 million from $7.7 million
a year ago, according to the mean estimate from 4 analysts,
based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Kiniksa
Pharmaceuticals
Ltd is for a loss of 44 cents per share. For the same quarter
last year, the company reported a loss of 61 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Kiniksa
Pharmaceuticals Ltd is $23.5​, above​ its last closing price
of $10.29. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2022  -0.40       -0.41      -0.36     Beat    11.5
 Dec. 31 2022  -0.42       -0.42      -0.53     Missed  -26.2
 Sep. 30 2021  -0.65       -0.65      -0.44     Beat    32​
 Jun. 30 2021  -0.94       -0.79      -0.61     Beat    23
 ​​Mar.        -0.63       -0.72      -0.72     Met     0.7
 31 2021                                                
 Dec. 31 2020  -0.61       -0.62      -0.79     Missed  -26.9​
 Sep. 30 2020  -0.60       -0.60      -0.66     Missed  -9.1
 Jun. 30 2020  -0.60       -0.63      -0.65     Missed  -3.8
 This summary was machine generated July 29 at 18:33 GMT.  All
figures in US dollars  unless otherwise stated